SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is currently under intense scrutiny as it approaches its earnings release, with investors weighing the company's 'Win Now' turnaround strategy against ongoing concerns regarding market share, tariff-driven costs, and performance in the China market. While some in the community see the current multi-year lows as a compelling buying opportunity, others remain skeptical, citing continued bearish price action and poor sentiment as indicators that the stock may face further downside before a meaningful recovery.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the company's long-awaited 10-K filing and Q4 earnings call, with community sentiment fueled by debt reduction progress and the strong performance of key holdings like Applied Digital and BW. The community is actively debating the potential for a valuation re-rating and a short squeeze, balancing caution over compliance deadlines against bullish conviction in the firm's turnaround strategy.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing significant volatility driven by high short interest and retail sentiment surrounding a potential short squeeze, while investors debate the company's long-term valuation amid broader geopolitical concerns. Community discussion is focused on the tension between strong enterprise deal pipelines and technical selling pressure, with many traders closely monitoring support levels for a potential reversal.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is experiencing heightened volatility and intense social media debate, driven by skepticism over its aggressive debt-financed Bitcoin accumulation strategy amidst cooling market conditions. The community remains deeply polarized, with bulls viewing recent price dips as a long-term loading opportunity while bears increasingly voice concerns regarding potential dilution, liquidity risks, and the stock's sensitivity to broader macroeconomic pressures.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is seeing a significant boost in sentiment following the official commercial launch of YARTEMLEA, as investors are actively tracking shipping updates and initial hospital adoption to validate the revenue potential of the drug. Community discourse is heavily focused on the company's ability to maintain a strong cash position while managing short interest, with many hoping that the confirmation of sales will finally force a break from recent price consolidation and attract institutional capital.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is currently trending as investors anticipate pivotal late-breaking phase 3 data for its lead asset, Sonelokimab, at the American Academy of Dermatology annual meeting. The community is focused on the potential for Sonelokimab to be validated as a "best-in-class" therapy for hidradenitis suppurativa, with active discussions centering on the significance of week-40 long-term durability results and the ongoing potential for a lucrative strategic acquisition by major pharmaceutical players.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Luckin Coffee is trending as investors react to the company's reported acquisition of Blue Bottle Coffee by its majority shareholder, Centurium Capital, and a significant 5% stake accumulation by First Beijing Investment. The community is actively debating whether this move signals a broader international expansion strategy and potential future relisting on major U.S. exchanges, while many users are focused on identifying the long-term value amid ongoing volatility and concerns regarding majority-owner control.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors monitor ongoing updates regarding the Tanbreez project's feasibility study and potential processing flowsheets, which management has signaled could lead to significant NPV revisions. The community remains highly polarized, with many long-term shareholders expressing conviction in the project's strategic value for western supply chains, while others debate the accuracy of historical economic reporting and the impact of the company's recent operational acquisitions in Greenland.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility driven by concerns over new import tariffs, leading to a sharp sell-off as investors weigh the impact on the company's heavily China-dependent supply chain. While some traders are betting on a short squeeze or a potential rebound if tariffs are eased, the community remains deeply divided, with many debating whether the stock's recent decline represents an oversold buying opportunity or a deeper fundamental issue.

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals is trending after receiving FDA approval for EMPAVELI to treat rare kidney diseases, a long-awaited catalyst that investors hope will diversify revenue and bolster the company's valuation. Community discussion is heavily focused on the potential for this approval to spark a long-term turnaround, with many traders debating the stock's M&A prospects and its ability to finally sustain growth against competitive market pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Large Cap Stocks To Follow Now - March 31st

Invesco QQQ, NVIDIA, and Tesla are the three Large Cap stocks to watch today, according to MarketBeat's stock screener tool. Large-cap stocks are shares of companies with a large market capitalizationtypically above about $10 billion, though exact cutoffs varyrepresenting well-established, mature...

Mega-cap dividend stock targets $9 trillion valuation

Meta Platforms recently disclosed a new stock option plan for its top executives that won't pay out unless the company's market cap skyrockets from roughly $1.36 trillion to $9 trillion by 2031. That...

Nvidia's $2 billion bet reveals its next big target

Nvidia (NVDA) started as a video game chipmaker, but became so much more thanks to smart investments. Today, along with GPUs, it makes CPUs, networking equipment, and AI inference accelerators.According to the company's 10-K form, in fiscal year 2026, its networking revenue totaled $31.4 billion...

Top Technology Stocks To Consider - March 31st

NVIDIA, Micron Technology, Meta Platforms, Sandisk, Microsoft, Alphabet, and Advanced Micro Devices are the seven Technology stocks to watch today, according to MarketBeat's stock screener tool. Technology stocks are shares of companies whose primary business involves developing, manufacturing, or...

AI & Quantum Opportunities After Tech Sell-Off: 2 Stocks for April 

NVIDIA and IBM emerge as top picks as AI and quantum trends endure a tech sell-off driven by war, inflation fears and energy shocks.

Michael Burry Says 'Shorts Are Not Forever' As Palantir, Nvidia Stocks Wrap A Rough Quarter

Michael Burry seems to hint that his controversial AI short was successful as Palantir and Nvidia closed out a rough quarter.read more...

<ul class="summary-bullets"><li>Goldman Sachs says rising demand for advanced computing power in specialized industries continues to strengthen Nvidia’s growth prospects.</li><li>Strategic partnerships with biotech firms are emerging as a major catalyst, enabling Nvidia to test and refine its AI models in real-world lab settings.</li><li>Nvidia’s investment in Recursion Pharmaceuticals highlights tangible AI-driven efficiencies.</li></ul>Goldman Sachs reportedly sees momentum for Nvidia Corp. (NVDA) as healthcare and life sciences companies accelerate their adoption of artificial intelligence.The firm stated that expanding use cases in drug development and clinical research may unlock meaningful upside for the semiconductor leader.<h2 class="st-heading-2">Healthcare Partnerships To Drive Nvidia Growth</h2>According to a CNBC&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cnbc.com/2026/03/31/goldman-is-betting-nvidia-will-get-a-boost-from-health-care-as-industry-builds-out-ai-capabilities-.html">report</a>, Goldman Sachs reiterated its ‘Buy’ rating on Nvidia, assigning a price target of $250, implying a potential 51% upside from the stock’s closing price on Monday, as analysts point to growing demand for AI-driven computing across specialized industries.Analyst Salveen Richter highlighted Nvidia’s collaborations with biotech and life sciences firms as a key growth engine. By working directly with these companies, Nvidia can validate its AI models in laboratory environments while expanding applications in areas such as digital health records, automation, and manufacturing.&nbsp;The company is also advancing “digital twin” simulations, which replicate real-world processes to enhance efficiency and reduce costs, Salveen added.&nbsp;<a href="https://stocktwits.com/symbol/NVDA">Nvidia’s stock</a> traded over 3% higher on Tuesday mid-morning. However, on Stocktwits, retail sentiment around the stock remained in ‘bearish’ territory amid ‘low’ message volume levels.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_31_115300_png_9d8d5a958c.webp" alt="NVDA’s Sentiment Meter and Message Volume as of 12:00 p.m. ET on Mar. 31, 2026 | Source: Stocktwits" width="944" height="114"><figcaption>NVDA’s Sentiment Meter and Message Volume as of 12:00 p.m. ET on Mar. 31, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Recursion Collaboration Shows Results</h2>Nvidia’s 2023 investment in Recursion Pharmaceuticals Inc. (RXRX) continues to demonstrate the potential of AI in drug discovery.&nbsp;The biotech firm reported that its technology platform enables researchers to dramatically reduce the number of compounds synthesized while also shortening the timeline to begin human testing. Processes that once took years can now move forward in a fraction of the time, Goldman Sachs noted.According to the report, Recursion executives also emphasized how machine learning improves clinical trial design. The technology helps identify suitable patient groups, streamline data analysis, and enhance recruitment efforts.&nbsp;NVDA stock has declined by over 8% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrvl-stock-rallies-nvidia-investment-ai-infrastructure-partnership/cZEPvgNRIVg">MRVL Stock Rallies On $2B Nvidia Investment, AI Infrastructure Partnership</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A close-up of a printed circuit board is seen with the Nvidia logo displayed on a screen in the background. (Photo by Nikos Pekiaridis/NurPhoto via Getty Images)

Nvidia’s Expanding Role In AI-Driven Drug Discovery, Clinical Research Could Fuel Growth, Says Goldman Sachs

Goldman Sachs maintained its ‘Buy’ recommendation on Nvidia and set a $250 price target, indicating roughly 51% potential upside from Monday’s closing level.

Equity

Goldman Sachs maintained its ‘Buy’ recommendation on Nvidia and set a $250 price target, indicating roughly 51% potential upside from Monday’s closing level.


Nvidia's web of AI investments

CNBC's Kristina Partsinevelos reports the latest news surrounding Nvidia...

Why NVIDIA's $2B Bet Validates Marvell

Marvell Technology has successfully navigated the transition from legacy hardware to the forefront of the AI infrastructure explosion.

AVGO's Gross Margin Contracts Sequentially: Is Growth Getting Harder?

Broadcom's gross margin keeps slipping as AI-fueled semiconductor growth reshapes its mix, even as strong revenue and surging AI demand drive an upbeat outlook.


NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Stocktwits

Stocktwits Polls

Markets are reacting violently to conflicting headlines and tweets regarding the status of the ongoing conflict in Iran.

Traders are debating if the current market rally is driven by institutional window dressing for the end of the month and quarter.

Short sellers are being squeezed as investors double down on dominant AI-related hardware and semiconductor stocks.

Focus is shifting toward strategic partnerships and critical infrastructure scaling within the evolving data center ecosystem.

Small-time traders are expressing extreme frustration over perceived market manipulation and the rapid, confusing price action.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$1.76	--	--	N/A
Q4 '25	$1.54	$1.62	5.54%	BEAT
Q3 '25	$1.26	$1.30	3.52%	BEAT
Q2 '25	$1.01	$1.05	4.12%	BEAT
Q1 '25	$0.73	$0.81	10.27%	BEAT

NVDA
NVIDIA Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest NVDA News

NVDANVIDIA Corp